• Virax Biolabs will hold an extraordinary general meeting in Glasgow on Aug. 14, 2026.
• Shareholders will vote on increasing authorized share capital to US$12.5 million, or 500,000,000 ordinary shares, from US$50,000, or 2,000,000 shares.
• A separate vote will seek adoption of amended and restated memorandum and articles of association to reflect the share capital increase.
• Another resolution would allow the meeting to be adjourned if more time is needed to secure votes on the proposals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-326851), on July 31, 2026, and is solely responsible for the information contained therein.